Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study - Ziprasidone vs. Clozapine for schizophrenia ans cannabis use disorder
- Conditions
- Patients with schizophrenia and cannabis abuse/dependency will be randomized to ziprasidone or clozapine treatment. Dose of medication and frequency of administration will be flexible and adjustable depending on clinical requirements. Duration of therapeutic trial:12 months
- Registration Number
- EUCTR2005-003156-35-DE
- Lead Sponsor
- Department of Psychiatry and Psychotherapy (Cologne)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 50
1.Patients with schizophrenia, schizophreniform or schizoaffective disorder according to DSM-IV (295.xx) and ICD-10 (F20, F23.2, F25) as well as cannabis abuse or dependence according to DSM-IV (305.20; 304.30) and ICD-10 (F12.1, F12.2)
2.Written informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
1.Further relevant neuropsychiatric disorders
2.Prominent (acute) positive symptoms at the timepoint of inclusion
3.Previous treatments with ziprasidone or clozapine with significant side effects
4.No availability of a family member or significant other for the collateral interviews of the follow-up evaluations
5.No compliance with the requirements of the study / lack of or questionable capability of giving informed consent
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method